Abstract
Antinuclear antibodies (ANAs) are a diverse group of autoantibodies that recognize nuclear macromolecules and their complexes. ANAs represent key biomarkers in the evaluation of rheumatic diseases, most prominently systemic lupus erythematosus (SLE), and ANA testing is commonly performed in the clinical setting. In addition, ANA testing is now used to assess eligibility for participation in clinical trials of new therapeutic agents for SLE. ANAs can be assayed by various techniques, with the fluorescent ANA assay often viewed as the gold standard. Whereas a positive ANA test represents a classification criterion for SLE, up to 20–30% of the healthy population, depending on the assay used, is positive for an ANA, complicating the use of this test for diagnosis or the detection of preclinical autoimmunity. Furthermore, ANAs might be expressed in SLE less commonly than often thought. This Perspectives article discusses important questions about the use of ANA testing in both the clinical and research settings.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Tan, E. M. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv. Immunol. 44, 93–151 (1989).
Kavanaugh, A., Tomar, R., Reveille, J., Solomon, D. H. & Homburger, H. A. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch. Pathol. Lab. Med. 124, 71–81 (2000).
Meroni, P. L. & Schur, P. H. ANA screening: an old test with new recommendations. Ann. Rheum. Dis. 69, 1420–1422 (2010).
Agmon-Levin, N. et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann. Rheum. Dis. 73, 17–23 (2014).
Solomon, D. H., Kavanaugh, A. J. & Schur, P. H. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. 47, 434–444 (2002).
Tan, E. M. et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum. 40, 1601–1611 (1997).
Abeles, A. M. & Abeles, M. The clinical utility of a positive antinuclear antibody test result. Am. J. Med. 126, 342–348 (2013).
Chan, E. K. et al. Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015. Lupus 25, 797–804 (2016).
Damoiseaux, J. et al. International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. Auto Immun. Highlights 7, 1 (2016).
Schulte-Pelkum, J., Fritzler, M. & Mahler, M. Latest update on the Ro/SS-A autoantibody system. Autoimmun. Rev. 8, 632–637 (2009).
Ghillani, P. et al. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60 kDa antibodies: results of a multicentric study. Autoimmun. Rev. 10, 509–513 (2011).
Fredi, M. et al. Rare autoantibodies to cellular antigens in systemic lupus erythematosus. Lupus 23, 672–677 (2014).
Viana, V. T., Durcan, L., Bonfa, E. & Elkon, K. B. Ribosomal P antibody: 30 years on the road. Lupus 26, 453–462 (2017).
Pisetsky, D. S. The translocation of nuclear molecules during inflammation and cell death. Antioxid. Redox Signal. 20, 1117–1125 (2014).
Vallin, H., Perers, A., Alm, G. V. & Ronnblom, L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-α inducer in systemic lupus erythematosus. J. Immunol. 163, 6306–6313 (1999).
Hua, J., Kirou, K., Lee, C. & Crow, M. K. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 54, 1906–1916 (2006).
Eloranta, M. L. et al. Regulation of the interferon-α production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum. 60, 2418–2427 (2009).
Kirou, K. A. et al. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 52, 1491–1503 (2005).
Balboni, I. et al. Interferon-α induction and detection of anti-Ro, anti-La, anti-Sm, and anti-RNP autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis. Arthritis Rheum. 65, 2424–2429 (2013).
Hoffman, I. E. et al. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann. Rheum. Dis. 63, 1155–1158 (2004).
To, C. H. & Petri, M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum. 52, 4003–4010 (2005).
Ching, K. H. et al. Two major autoantibody clusters in systemic lupus erythematosus. PLoS ONE 7, e32001 (2012).
Gunnarsson, R., Hetlevik, S. O., Lilleby, V. & Molberg, O. Mixed connective tissue disease. Best Pract. Res. Clin. Rheumatol. 30, 95–111 (2016).
Gunawardena, H. The clinical features of myositis-associated autoantibodies: a review. Clin. Rev. Allergy Immunol. 52, 45–57 (2017).
Hepburn, A. L. The LE cell. Rheumatology (Oxford) 40, 826–827 (2001).
Friou, G. J. Antinuclear antibodies: diagnostic significance and methods. Arthritis Rheum. 10, 151–159 (1967).
Fritzler, M. J. Choosing wisely: review and commentary on anti-nuclear antibody (ANA) testing. Autoimmun. Rev. 15, 272–280 (2016).
Wiik, A. S., Hoier-Madsen, M., Forslid, J., Charles, P. & Meyrowitsch, J. Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J. Autoimmun. 35, 276–290 (2010).
Russell, A. S. & Johnston, C. Relative value of commercial kits for ANA testing. Clin. Exp. Rheumatol. 21, 477–480 (2003).
Gonzalez, D. A. et al. Autoantibody detection with indirect immunofluorescence on HEp-2 cells: starting serum dilutions for systemic rheumatic diseases. Immunol. Lett. 140, 30–35 (2011).
Copple, S. S. et al. Screening for IgG antinuclear autoantibodies by HEp-2 indirect fluorescent antibody assays and the need for standardization. Am. J. Clin. Pathol. 137, 825–830 (2012).
Abeles, A. M., Gomez-Ramirez, M., Abeles, M. & Honiden, S. Antinuclear antibody testing: discordance between commercial laboratories. Clin. Rheumatol. 35, 1713–1718 (2016).
Hahm, D. & Anderer, U. Establishment of HEp-2 cell preparation for automated analysis of ANA fluorescence pattern. Cytometry A 69, 178–181 (2006).
Bizzaro, N. et al. Automated antinuclear immunofluorescence antibody screening: a comparative study of six computer-aided diagnostic systems. Autoimmun. Rev. 13, 292–298 (2014).
Krause, C. et al. EUROPattern Suite technology for computer-aided immunofluorescence microscopy in autoantibody diagnostics. Lupus 24, 516–529 (2015).
Fritzler, M. J. & Miller, B. J. Detection of autoantibodies to SS-A/Ro by indirect immunofluorescence using a transfected and overexpressed human 60 kD Ro autoantigen in HEp-2 cells. J. Clin. Lab. Anal. 9, 218–224 (1995).
Peene, I. et al. Sensitivity of the HEp-2000 substrate for the detection of anti-SSA/Ro60 antibodies. Clin. Rheumatol. 19, 291–295 (2000).
Hoffman, I. E., Peene, I., Veys, E. M. & De Keyser, F. Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests. Clin. Chem. 48, 2171–2176 (2002).
Mariz, H. A. et al. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum. 63, 191–200 (2011).
Satoh, M. et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum. 64, 2319–2327 (2012).
Hilario, M. O. et al. Frequency of antinuclear antibodies in healthy children and adolescents. Clin. Pediatr. (Phila.) 43, 637–642 (2004).
Olsen, N. J. et al. Autoantibody profiling to follow evolution of lupus syndromes. Arthritis Res. Ther. 14, R174 (2012).
Olsen, N. J. & Karp, D. R. Autoantibodies and SLE: the threshold for disease. Nat. Rev. Rheumatol. 10, 181–186 (2014).
Conrad, K., Rober, N., Andrade, L. E. & Mahler, M. The clinical relevance of anti-DFS70 autoantibodies. Clin. Rev. Allergy Immunol. 52, 202–216 (2017).
Gundin, S. et al. Measurement of anti-DFS70 antibodies in patients with ANA-associated autoimmune rheumatic diseases suspicion is cost-effective. Auto Immun. Highlights 7, 10 (2016).
Wallace, D. J. et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61, 1168–1178 (2009).
Furie, R. et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63, 3918–3930 (2011).
van Vollenhoven, R. F. et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann. Rheum. Dis. 71, 1343–1349 (2012).
Petri, M. A. et al. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum. 65, 2143–2153 (2013).
Emlen, W. & O'Neill, L. Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum. 40, 1612–1618 (1997).
Sjowall, C. et al. Abnormal antinuclear antibody titers are less common than generally assumed in established cases of systemic lupus erythematosus. J. Rheumatol. 35, 1994–2000 (2008).
Gniewek, R. A., Stites, D. P., McHugh, T. M., Hilton, J. F. & Nakagawa, M. Comparison of antinuclear antibody testing methods: immunofluorescence assay versus enzyme immunoassay. Clin. Diagn. Lab. Immunol. 4, 185–188 (1997).
Tan, E. M. et al. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum. 42, 455–464 (1999).
Fritzler, M. J. et al. A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories. J. Rheumatol. 30, 2374–2381 (2003).
Fenger, M. et al. Detection of antinuclear antibodies by solid-phase immunoassays and immunofluorescence analysis. Clin. Chem. 50, 2141–2147 (2004).
Op De Beeck, K. et al. Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay. Autoimmun. Rev. 10, 801–808 (2011).
Stearns, N. A., Zhou, S., Petri, M., Binder, S. R. & Pisetsky, D. S. The use of poly-L-lysine as a capture agent to enhance the detection of antinuclear antibodies by ELISA. PLoS ONE 11, e0161818 (2016).
Kavai, M., Bányai, A., Zsindely, A., Sonkoly, I. & Szegedi, G. Enzyme-linked immunosorbent assay for antibodies to native DNA in sera of patients with SLE. J. Immunol. Methods 48, 169–175 (1982).
Stokes, R. P., Cordwell, A. & Thompson, R. A. A simple, rapid ELISA method for the detection of DNA antibodies. J. Clin. Pathol. 35, 566–573 (1982).
Rubin, R. L., Joslin, F. G. & Tan, E. M. An improved ELISA for anti-native DNA by elimination of interference by anti-histone antibodies. J. Immunol. Methods 63, 359–366 (1983).
Sutjita, M., Hohmann, A., Boey, M. L. & Bradley, J. Microplate ELISA for detection of antibodies to DNA in patients with systemic lupus erythematosus: specificity and correlation with Farr radioimmunoassay. J. Clin. Lab. Anal. 3, 34–40 (1989).
Lopez-Longo, F. J. et al. Simultaneous identification of various antinuclear antibodies using an automated multiparameter line immunoassay system. Lupus 12, 623–629 (2003).
Damoiseaux, J., Boesten, K., Giesen, J., Austen, J. & Tervaert, J. W. Evaluation of a novel line-blot immunoassay for the detection of antibodies to extractable nuclear antigens. Ann. NY Acad. Sci. 1050, 340–347 (2005).
Shovman, O. et al. Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies. Ann. NY Acad. Sci. 1050, 380–388 (2005).
Binder, S. R. Autoantibody detection using multiplex technologies. Lupus 15, 412–421 (2006).
Moder, K. G. et al. Measurement of antinuclear antibodies by multiplex immunoassay: a prospective, multicenter clinical evaluation. J. Rheumatol. 34, 978–986 (2007).
Op De Beeck, K. et al. Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis. Autoimmun. Rev. 12, 137–143 (2012).
Tansley, S. L. & McHugh, N. J. Myositis specific and associated autoantibodies in the diagnosis and management of juvenile and adult idiopathic inflammatory myopathies. Curr. Rheumatol. Rep. 16, 464 (2014).
Satoh, M., Tanaka, S. & Chan, E. K. The uses and misuses of multiplex autoantibody assays in systemic autoimmune rheumatic diseases. Front. Immunol. 6, 181 (2015).
Robinson, W. H., Steinman, L. & Utz, P. J. Protein arrays for autoantibody profiling and fine-specificity mapping. Proteomics 3, 2077–2084 (2003).
Li, Q. Z. et al. Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin. Exp. Immunol. 147, 60–70 (2007).
Arbuckle, M. R. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526–1533 (2003).
McClain, M. T. et al. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat. Med. 11, 85–89 (2005).
Lu, R. et al. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J. Autoimmun. 74, 182–193 (2016).
Munroe, M. E. et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann. Rheum. Dis. 75, 2014–2021 (2016).
Wandstrat, A. E. et al. Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus. J. Autoimmun. 27, 153–160 (2006).
Mahler, M. et al. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J. Rheumatol. 39, 2104–2110 (2012).
Hahn, B. H. Antibodies to DNA. N. Engl. J. Med. 338, 1359–1368 (1998).
Pisetsky, D. S. Anti-DNA antibodies — quintessential biomarkers of SLE. Nat. Rev. Rheumatol. 12, 102–110 (2016).
Schur, P. H. & Sandson, J. Immunologic factors and clinical activity in systemic lupus erythematosus. N. Engl. J. Med. 278, 533–538 (1968).
Ward, M. M., Pisetsky, D. S. & Christenson, V. D. Antidouble stranded DNA antibody assays in systemic lupus erythematosus: correlations of longitudinal antibody measurements. J. Rheumatol. 16, 609–613 (1989).
Neogi, T., Gladman, D. D., Ibanez, D. & Urowitz, M. Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. J. Rheumatol. 33, 1785–1788 (2006).
Biesen, R. et al. Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus. Arthritis Res. Ther. 13, R26 (2011).
Venner, A. A. et al. Comparison of three anti-dsDNA assays: performance and correlation with systemic lupus erythematosus disease activity. Clin. Biochem. 46, 317–320 (2013).
Bonroy, C., Verfaillie, C., De Witte, E. & De Keyser, F. Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al. Arthritis Rheumatol. 66, 479–480 (2014).
Enocsson, H. et al. Four anti-dsDNA antibody assays in relation to systemic lupus erythematosus disease specificity and activity. J. Rheumatol. 42, 817–825 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Pisetsky, D. Antinuclear antibody testing — misunderstood or misbegotten?. Nat Rev Rheumatol 13, 495–502 (2017). https://doi.org/10.1038/nrrheum.2017.74
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.74
This article is cited by
-
Cognitive deficits associated with novel intrathecal anti-nuclear antibodies
Molecular Psychiatry (2024)
-
Clinical diagnoses associated with a positive antinuclear antibody test in patients with and without autoimmune disease
BMC Rheumatology (2023)
-
Risk of systemic lupus erythematosus flares according to autoantibody positivity at the time of diagnosis
Scientific Reports (2023)
-
nanoGold and µGold inhibit autoimmune inflammation: a review
Histochemistry and Cell Biology (2023)
-
Salivary anti-nuclear antibody (ANA) mirrors serum ANA in systemic lupus erythematosus
Arthritis Research & Therapy (2022)